S. Zalba

发表

Cell membrane modulation as adjuvant in cancer therapy.

S. Zalba, T. T. ten Hagen, T. L. T. ten Hagen, 2017, Cancer treatment reviews.

Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody

G. Koning, R. Debets, S. Zalba, 2016, International journal of nanomedicine.

Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice.

C. Tros de Ilarduya, S. Zalba, D. Moreno, 2010, European journal of pharmaceutics and biopharmaceutics.

Application of non-aggressive sample preparation and electrothermal atomic absorption spectrometry to quantify platinum in biological matrices after cisplatin nanoparticle administration

Í. Navarro-Blasco, S. Zalba, D. Moreno, 2010 .

Biopharmaceutic and pharmacodynamic modeling of the in vitro antiproliferative effect of new controlled delivery systems of cisplatin.

H. Colom, C. Tros de Ilarduya, I. Trocóniz, 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Immunoliposomes in clinical oncology: State of the art and future perspectives

S. Zalba, M. Garrido, M. Merino, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Efficient serum-resistant lipopolyplexes targeted to the folate receptor.

C. Tros de Ilarduya, L. García, Koldo Urbiola, 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and α-PD-1

P. Berraondo, I. Trocóniz, D. D. de Alwis, 2021, British Journal of Cancer.

Efficient gene delivery by EGF-lipoplexes in vitro and in vivo.

N. Düzgüneş, M. Buñuales, C. T. de Ilarduya, 2011, Nanomedicine.

Stealth nanoparticles in oncology: Facing the PEG dilemma.

S. Zalba, T. T. ten Hagen, M. Garrido, 2022, Journal of controlled release : official journal of the Controlled Release Society.

EGFR targeted thermosensitive liposomes: A novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery.

G. Koning, S. Zalba, T. T. ten Hagen, 2016, Colloids and surfaces. B, Biointerfaces.

A new immune-nanoplatform for promoting adaptive antitumor immune response.

P. Berraondo, I. Trocóniz, S. Zalba, 2019, Nanomedicine : nanotechnology, biology, and medicine.

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs

R. Debets, S. Zalba, A. M. Contreras-Sandoval, 2020, Pharmaceutics.

Liposomes, a promising strategy for clinical application of platinum derivatives

S. Zalba, M. Garrido, 2013, Expert opinion on drug delivery.

Application of different methods to formulate PEG-liposomes of oxaliplatin: evaluation in vitro and in vivo.

C. Tros de Ilarduya, I. Trocóniz, S. Zalba, 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model.

G. Koning, I. Trocóniz, C. T. de Ilarduya, 2016, Nanomedicine.

Design and in-vitro/in-vivo evaluation in colon cancer cells of targeted oxaliplatin liposomes to epidermal growth factor receptor by conjugation of different ligands

S. Zalba, 2015 .

Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles.

J. Brouwers, M. Verheij, S. Zalba, 2020, Nanoscale.

Drug transport kinetics of intravascular triggered drug delivery systems

D. Haemmerich, M. Dreher, S. Zalba, 2021, Communications Biology.

Drug transport kinetics of intravascular triggered drug delivery systems

D. Haemmerich, M. Dreher, S. Zalba, 2021, Communications biology.

Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response

R. Debets, S. Zalba, A. Seynhaeve, 2019, International journal of nanomedicine.